The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors

Immune Checkpoint Inhibitors and Tumor Mutational Burden The FDA has approved immune checkpoint inhibitors for solid tumors of any histologic origin with more than 10 mutations per megabase of DNA....